SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

Abstract

Although clinical responses in liquid tumors and certain lymphomas have been reported, the clinical efficacy of histone deacetylase inhibitors in solid tumors has been limited. This may be in part due to the poor pharmacokinetic of these drugs, resulting in inadequate tumor concentrations of the drug. SB939 is a new hydroxamic acid based histone deacetylase inhibitor with improved physicochemical, pharmaceutical, and pharmacokinetic properties. In vitro, SB939 inhibits class I, II, and IV HDACs, with no effects on other zinc binding enzymes, and shows significant antiproliferative activity against a wide variety of tumor cell lines. It has very favorable pharmacokinetic properties after oral dosing in mice, with >4-fold increased bioavailability and 3.3-fold increased half-life over suberoylanilide hydroxamic acid (SAHA). In contrast to SAHA, SB939 accumulates in tumor tissue and induces a sustained inhibition of histone acetylation in tumor tissue. These excellent pharmacokinetic properties translated into a dose-dependent antitumor efficacy in a xenograft model of human colorectal cancer (HCT-116), with a tumor growth inhibition of 94% versus 48% for SAHA (both at maximum tolerated dose), and was also effective when given in different intermittent schedules. Furthermore, in APC min mice, a genetic mouse model of early-stage colon cancer, SB939 inhibited adenoma formation, hemocult scores, and increased hematocrit values more effectively than 5-fluorouracil. Emerging clinical data from phase I trials in cancer patients indicate that the pharmacokinetic and pharmacologic advantages of SB939 are translated to the clinic. The efficacy of SB939 reported here in two very different models of colorectal cancer warrants further investigation in patients. Mol Cancer Ther; 9(3); 642-52. ©2010 AACR.

Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection

“…Therefore, concentrations of orally active givinostat used in vivo and in vitro in our study are clinically feasible, safe, and effective. Although we did not measure vorinostat plasma levels in the treated NOD mice, the dose used was clinically relevant, because oral administration of 50 mg/kg of vorinostat in mice in other studies resulted in a plasma concentrations equal to those obtained by safe and tolerated doses in humans (24,25).…”

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

“…Tumor growth inhibition was calculated as described previously. 10 For the efficacy studies, mice were treated by oral gavage (10 ml/kg body weight) with doses from 50 to 150 mg/kg SB1518.…”

Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance

“…(Table 3). Besides, induction of cell cycle arrest and elevated cleavage of poly ADP ribose polymerase (hallmark of apoptosis) in a dose-dependent manner was seen in the defined model upon the therapeutic intervention using pracinostat (Novotny-Diermayr et al 2010). Superior pharmacokinetic properties were seen for pracinostat compared to SAHA in nude mice models.…”

“…Pracinostat has shown an average 2-fold greater potency than SAHA against classical HDACs excluding HDAC6. Experiments dealing with the comparative potency of pracinostat and FDA approved SAHA across distinct cell lines have clearly shown that the former inhibitor is 3.5-fold more potent than the latter on an average (Novotny-Diermayr et al 2010). However, in case of colorectal cancer cell line (HCT-116), pracinostat proved to be 7.6-fold more potent than SAHA (Pracinostat IC 50 ¼ 0.48 mmol/L and for SAHA 2.14 mmol/L).…”

“…This oral pan-HDAC inhibitor has been found to inhibit class I, II and class IV HDACs as determined by in vitro assays (Novotny-Diermayr et al 2010). This inhibitor has shown marked antiproliferative effect against multiple tumour cell lines (NovotnyDiermayr et al 2010).…”